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Abstract: A new chewable combined oral contraceptive pill containing ethinyl estradiol (EE) 
0.025 mg and norethindrone (NE) 0.8 mg in a 24/4 regimen was approved for marketing in 
December 2010. Each of the four inactive tablets contains 75 mg ferrous fumarate, which has no 
therapeutic benefit. The tablet can be taken with food but not water as this affects the absorption 
of EE. The Pearl index based on intention to treat women aged 18–35 years has been reported at 
2.01 (confidence interval [CI] 1.21, 3.14) and for the whole population 1.65 (CI 1.01, 2.55). The 
effect of a body mass index of .35 was not studied. Regular withdrawal bleeding occurred for 
78.6% of women in Cycle 1, but by Cycle 13 almost half the women failed to have a withdrawal 
bleed. This new formulation provides an intermediate dose of an EE/NE combination that will 
be useful for women experiencing breakthrough bleeding on the lower-dose EE/NE pill. The 
convenience of a low-dose pill, which can be chewed without the need for water, will be useful 
to enable women who have forgotten a pill to take one whenever they remember, provided they 
carry it with them. The advantage of a 24/4 regimen is better suppression of follicular devel-
opment in the pill-free interval and may be beneficial for women who experience menstrual 
cycle-related problems, such as heavy bleeding or dysmenorrhea.
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Introduction
The combined oral contraceptive pill (COC) was first marketed in 1960. In the inter-
vening 50 years, it has undergone many changes, including a reduction in dose of 
both the estrogen and progestin components, different administration regimens, and 
the development of new progestins more similar in structure to progesterone. The 
aim of these changes was to reduce the risk of potentially serious side effects, such as 
venous and arterial thrombosis and hypertension, as well as to make the COC more 
acceptable to women by reducing the likelihood of troublesome side effects such as 
nausea, vomiting, weight gain, headaches, breast tenderness, and pain, which were 
common with the original high-dose COCs. The dose of estrogen has been reduced 
from 0.1 mg to as low as 0.02 mg. Several COCs containing estradiol instead of ethinyl 
estradiol (EE) have been developed, although these are not yet available in the USA. 
The recent introduction of a chewable COC adds another choice for women, especially 
those who find swallowing a pill, even if small, difficult or unacceptable.
Formulation of the chewable COC
Each active tablet of this newly released COC contains 0.025 mg EE and 0.8 mg 
norethindrone (NE) and, in each inactive tablet, 75 mg ferrous fumarate. EE is the 
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estrogen that is used in almost all COCs currently marketed 
and is available in combination with NE in a number of 
different formulations. This is the first COC that combines 
0.025 mg EE with 0.8 mg NE and offers an intermediate dose 
of both EE and NE compared with the range now available 
(EE 0.02–0.05 mg and NE 0.4–1.5 mg). Each cycle pack 
contains 24 light green active tablets and four brown inactive 
(placebo) tablets. The recommended regimen is one active 
tablet daily for 24 days followed by one placebo tablet daily 
for 4 days, providing a 28-day cycle. The placebo tablets 
do not serve any therapeutic purpose. The tablets are to be 
chewed and swallowed without water at approximately the 
same time each day.1
Pharmacology, mode of action  
and pharmacokinetics
Both EE and NE have been available in a variety of doses 
and combinations in COCs since the 1960s. NE has weak 
androgenicity and estrogenicity.2 Both EE and NE are 
  subject to first-pass metabolism after oral dosing, resulting 
in an absolute bioavailability of approximately 43% for EE 
and 64% for NE. Data from a study of 18 women taking the 
chewable COC indicate that maximum plasma EE and NE 
concentrations occur within 2 hours after oral administration. 
Following multiple doses of EE/NE chewable tablets, the 
mean maximum concentrations of EE and NE were increased 
by 14% and 126%, respectively, when compared with levels 
following a single dose. Mean EE and NE exposures (area 
under the time–concentration curve [AUC] values) were 
increased by 55% and 239%, respectively, as compared to 
single-dose administration.3
Food and water effect
Since these tablets are chewed rather than swallowed whole, 
a Phase III study looked at the effect of food on plasma lev-
els of EE and NE tablets taken either after food or fasting 
(Figures 1 and 2).3 Taking the tablet with food did not affect 
EE absorption but increased NE absorption by 10%. A single 
EE/NE tablet taken with food decreased the Cmax of NE by 
47% and but increased the AUC by 10%–14% and decreased 
the Cmax of EE by 39%, but not AUC. The US Federal Drug 
Administration (FDA) decided that, despite the effect of food 
on absorption, the tablets could be taken with or without 
food because these were the instructions given to subjects 
participating in the Phase III clinical trial.4
There was a small reduction in the Cmax for EE when 
EE/NE tablets were chewed with 45 mL water compared to 
the Cmax when tablets were chewed without water. The mean 
AUC value for EE and the mean Cmax and AUC values 
for NE followed by 45 mL water, compared with the Cmax 
when tablets were chewed and taken without water, were 
within 80%–125% of each other, indicating bioequivalence. 
  However, the mean Cmax for EE was 76.5% instead of $80% 
when compared to levels taken without water. As taking the 
tablet with water affects the bioavailability of EE but not NE, 
it is recommended that the tablets be chewed without water. 
As this tablet is meant to be chewed rather than swallowed, 
a study to determine any possibility of oral irritation was 
conducted as a single-center, open-label, uncontrolled study 
in 54 healthy women aged 18–44. The subjects chewed one 
EE/NE tablet per day without water for 24 days, irrespec-
tive of food intake. No evidence of any irritation of the oral 
cavity was demonstrated.3
As combinations of EE with NE have been widely 
available for many years, one of the few assessments car-
ried out on this chewable COC was serum sex hormone 
binding globulin (SHBG) concentration, which had more 
than doubled by day 24 of pill intake. Mean SHBG concen-
trations were increased by 170% from baseline. This is to 
be expected, as EE induces the synthesis of SHBG. SBHG 
concentrations had more than doubled by day 24 due to 
accumulation.5
The increase in SHBG suggests that, like many other 
COCs, this particular formulation may be useful to treat 
women with moderate acne.6 SHBG binds free testosterone, 
which is responsible for increased sebum production in the 
skin resulting in acne.7
Mode of action
All combined oral contraceptives act by suppression of 
gonadotropins. Although the primary mechanism is inhibi-
tion of ovulation, other alterations include increases in the 
viscosity of cervical mucus, which impedes sperm passage 
into the uterus, and changes in the endometrium, which 
reduce the likelihood of implantation.4
Overall assessment
A literature search found no published articles relating to 
this new 0.25 mg EE/0.8 mg NE COC. The only data avail-
able are from the Phase III studies submitted to the FDA 
in the registration application.1,3–6 A total of 1700 subjects 
were enrolled in a Phase III study, of whom 1677 women 
took at least one dose of the study drug and were included 
in the intent-to-treat population analysis for safety. A modi-
fied intent-to-treat population (MITT) included all subjects 
who received at least one dose of the study drug and were 
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evaluated for pregnancy at least once after beginning the 
study medication. A subgroup of the MITT population, the 
pregnancy intent-to-treat population (PITT), included all 
subjects who were 18–35 years of age at enrollment, had 
received at least one dose of study drug, and were evalu-
ated for pregnancy at least once after beginning the study 
medication. The PITT consisted of 1251 women who were 
assessed over 12,297 treatment cycles during which no 
backup contraception was used (Table 1).4
There were 19 on-treatment pregnancies. The MITT 
population (a secondary efficacy population) consisted of 
1570 women aged 18–46 years at entry, who were assessed 
over 15,752 treatment cycles during which no backup 
contraception was used. A single on-treatment pregnancy 
occurred among the subjects who were .35 years of age 
at entry. The other pregnancies all occurred in women aged 
#35 years. The Pearl index5 for the PITT group was 2.01 
(CI 1.21, 3.14) and for the MITT population, 1.65 (CI 1.01, 
2.55). For the PITT cohort, the cumulative failure rate after 
13 cycles of treatment was 2% (95% CI 1.27%–3.13%), based 
on the 19 on-treatment pregnancies, and for the MITT group, 
1.75% (CI 1.27–2.4). The Pearl index for subjects in the PITT 
group with a body mass index (BMI) of #30 kg/m2 was 1.86 
(95% CI 1.04–3.06) compared with 2.89 (95% CI 0.79–7.38) 
for subjects with a BMI between 30 and 35 kg/m2, based 
on four pregnancies in this subgroup. The overall percent-
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Figure 1 Mean plasma ethinyl estradiol concentration versus time curves following administration of a NE/EE tablet under test and reference treatments (A) fed and (B) 
fasted conditions, respectively, to healthy female subjects (n = 13).
Abbreviations: EE, ethinyl estradiol; NE, norethindrone.
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Figure 2 Mean plasma norethindrone concentration versus time curves following administration of a NE/EE tablet under test and reference treatments (A) fed and (B) 
fasted conditions, respectively, to healthy female subjects (n = 13).
Abbreviations: EE, ethinyl estradiol; NE, norethindrone.
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age of subjects with BMI $ 30 kg/m2 in the entire treated 
population was 263/1677 (15.6%) compared with 21% of 
pregnant subjects with BMI $ 30 kg/m2.4 There is conflicting 
evidence on the effect of BMI on COC efficacy.8 The numbers 
in this Phase III study are too small to provide conclusive 
evidence of the effect of BMI on pregnancy rates with the 
chewable COC, especially as women with BMI .35 kg/m2 
were excluded from the study population.
Cycle control
Cycle control is an important consideration for women in 
choosing a COC. In this Phase III study, regular withdrawal 
bleeding occurred for 78.6% of women in Cycle 1 but by 
Cycle 13 this had reduced to 56.6%, indicating that by the 
final study cycle almost half the women failed to have a 
withdrawal bleed. There are no data available to indicate 
what percentage experienced more than one cycle with absent 
withdrawal bleeding. Breakthrough bleeding and or spotting 
(BTB) is common with most COCs during the initial cycles. 
With this COC, the percentage of cycles with BTB decreased 
from 31.3% in Cycle 2 to 22.5% in Cycle 13.4 The number of 
days with BTB decreased from 1.9 during Cycle 1 to 0.9 in 
Cycle 13. Overall, approximately 70% of subjects will have 
some intracyclic bleeding/spotting sometime in the first year 
of use. A total of 15 subjects (0.9%) discontinued the study 
prematurely due to unacceptable bleeding patterns including 
amenorrhea.
Although there are no published studies on this formula-
tion, the bleeding patterns are similar to those reported for 
an EE 0.02 mg/NE 0.5 mg combination, which reported 
amenorrhea in 20.7% of cycles compared with 7.1% for EE 
0.02 mg/levonorgestrel 0.1 mg.9
Overall assessment of safety
Among the safety issues of greatest concern associated 
with the use of hormonal contraceptives are those related to 
thrombotic and thromboembolic events such as deep vein 
thrombosis (DVT), pulmonary emboli, and stroke. In the 
present study, which contained safety data from more than 
1600 subjects and more than 15,500, 28-day treatment cycles, 
there was one report of DVT and no reports of pulmonary 
embolus or stroke. The risk of venous thromboembolism 
(VTE) in women using COCs is well established and is 
estimated to have an incidence rate of 1/1000 women.10 It 
usually occurs within the first 3–6 months of initiating COCs 
in women with hereditary thrombophilias.11 Other risk factors 
for VTE are smoking, immobility, increasing age, and BMI.12 
A single case of DVT in the clinical development program 
for EE/NE chewable tablets is not unexpected nor indicative 
of an increased risk of VTE. Although there is still some 
controversy about the risk of venous thromboembolism with 
the newer progestins, the consensus is that norethindrone, 
norethindrone acetate, and levonorgestrel are associated with 
the lowest risk of venous thromboembolic events.4
Apart from the single case of DVT reported in the pivotal 
study, eight other serious adverse events were reported that 
could be ascribed to this COC: depression and/or suicidal 
ideation (four), cholecystitis and/or cholecystectomy (two), 
and hypertension (two). These serious adverse events have 
been previously reported in association with COCs.
A total of 136 out of 1677 subjects (8.1%) experienced 
an adverse event leading to early withdrawal from the 
study. The most frequently reported adverse events leading 
to discontinuation and the percentage of subjects reporting 
these adverse events were nausea (1.0%), weight increase 
(0.8%), acne (0.8%), BTB (0.7%), altered mood (0.4%), 
hypertension (0.4%), irritability (0.3%), migraine (0.3%), 
decreased libido (0.3%), and mood swings (0.3%). The 
most commonly reported adverse events (.2%) – possibly 
related to treatment with the study drug and the percent-
age of subjects reporting them – included nausea (6.1%), 
headache (4.8%),   dysmenorrhea (3.9%), acne (3.2%), 
vulvovagina mycotic infection (3.1%), vomiting (2.7%), 
increased weight (2.3%), anxiety (2.1%), fungal infections 
(2.1%), and   diarrhea (2.0%).
Of the 1677 subjects who took study medication, 
143   discontinued due to an adverse event (8.5%). The most 
frequent adverse reactions leading to discontinuation were 
nausea (1.0%), weight increase (0.8%), acne (0.8%), metror-
rhagia (0.7%), altered mood (0.4%), hypertension (0.4%), 
irritability (0.3%), migraine (0.3%), decreased libido (0.3%), 
Table 1 Enrollments and early withdrawals
Total subjects enrolled 1700
Total subjects treated 1677 (100%)
MITT population 1570 (93.6%)
PITT population 1251 (74.6%)
Prematurely discontinued from the study 686 (40.9%)a
  Lost to follow-up 271 (16.2%)
  Withdrawal of consent 149 (8.9%)
  Adverse event E 143 (8.5%)
  Other 75 (4.5%)
  Protocol violation 25 (1.5%)
  Lack of efficacy (pregnancy) 23 (1.4%)
Notes: aPercentages based on total subjects treated (n = 1677). Adapted from table 2 
in US Center for Drug Evaluation and Research/FDA. Summary Review – Norethindrone 
(NE)  and  Ethinyl  Estradiol  (EE)  Chewable  Tablets  and  Ferrous  Fumarate  (FF)  Chewable 
Tablets. Silver Spring, MD: FDA; 2010. Available from: http://www.accessdata.fda.gov/
drugsatfda_docs/nda/2010/022573Orig1s000SumR.pdf. Accessed February 21, 2012.
Abbreviations: MITT, modified intent to treat population; PITT, pregnancy intent 
to treat population.
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and mood swings (0.3%). Low incidences of these side 
effects have been reported in virtually all hormonal contra-
ceptive studies.
As mentioned previously, there are no reports in the 
literature about the 0.025 mg EE/0.08 mg NE combined 
COC and there are no comparative studies as the only Phase 
III studies carried out were open-label single studies. There 
is another chewable COC with a similar drug combina-
tion currently approved in the USA containing 0.035 mg 
EE and 0.4 mg NE but this is to be taken once daily for 
21 days followed by one tablet of ferrous fumarate once 
daily for 7 days. The instructions for this COC indicate it 
can be can be swallowed whole or chewed with water and 
taken without regard to food.1 There are more than five 
other products with EE/NE combination approved for 
contraception. These products contain 0.035 mg EE or 
0.05 mg EE and either 0.5 mg NE or 1.0 mg NE. As EE 
and NE have been used in much higher doses in previous 
COC combinations, there are no safety issues with this 
latest chewable COC.
Low-dose COCs tend to have increased follicular 
  development in the pill free week compared to higher 
doses.13 The use of a 24/4 day regimen with low-dose 
formulations has generally been associated with less fol-
licular   development compared to a 21/7 day regimen,14 
although one study comparing a 24/4 day regimen of 
0.02 mg EE/1 mg NE with a 21/7 day regimen found no 
difference in follicle   development.15 A similar study of the 
same combination found that bleeding patterns were better 
with the 24/4 regimen with reduced intracyclic bleeding 
and shorter withdrawal bleeding.16 A Cochrane review was 
unable to detect any differences in effectiveness between 
COCs containing 0.02 mg EE or .0.02 mg EE but found 
that lower doses were associated with higher rates of bleed-
ing disturbances.17
Patient acceptability
Since its introduction in 1960, the COC has been embraced 
by women and is currently used by approximately 
100 million women worldwide.8 There are no acceptability 
studies available for this new chewable COC. Compliance in 
the Phase III study was difficult to access, but 39 women were 
withdrawn for apparent failure to comply with the protocol. 
However, both compliance studies and acceptability studies 
have been carried out on other COCs. Compliance with a 
daily oral preparation can be difficult. A study using an elec-
tronic device that recorded actual pill use found that 30% of 
women missed three or more pills in any given cycle.18 
In a French survey, of all unplanned pregnancies, 21% were 
using COC at time of conception.19
As this is a newly marketed product, no uptake or 
continuation rates are available. In a prospective study, 
Rosenberg found that 37% of pill users discontinued 
because of side effects, the majority in the first 2 months.20 
The major side effects were bleeding irregularities (12%), 
nausea (7%), weight gain (5%), mood changes (5%), breast 
tenderness (4%), and headaches (5%), with similar side 
effects to those reported with the new chewable COC. 
However, the incidence of these is lower with the new pill, 
which could be ascribed to the low dose of steroids in this 
formulation. The discontinuation rate for this Phase III trial 
was considerably lower at 6.2% but continuation rates in 
clinical trials are generally lower than when COCs are in 
general use.
Conclusion
This new chewable formulation, which was approved for 
sale in the USA in December 2010, offers an additional 
choice for women. There is only one other chewable pill 
on the market but this contains a higher dose of EE and is 
a 21/7 regimen. The advantage of a 24/4 regimen is bet-
ter suppression of follicular development in the pill-free 
interval, reducing the likelihood of breakthrough ovulation 
even further.21   Reducing the active pill-free interval has 
been shown to be beneficial for women who experience 
menstrual cycle-related problems such as heavy bleed-
ing or dysmenorrhea. The hormone-free interval of less 
than 7 days has additional benefits in managing hormone 
withdrawal symptoms such as menstrual migraine and 
efficacy may be improved in situations where pills are 
inadvertently missed or in women who are perceived as 
“poor” pill takers.22
The formulation of 0.025 mg EE/0.4 mg NE offers 
an intermediate dose of these common combinations of 
hormones. The efficacy is comparable to other marketed 
COCs. The bleeding pattern is comparable to other lower-
dose COCs. Some women may find the incidence of missed 
withdrawal bleeding stressful as they may interpret it as a 
sign of pregnancy. However, there are an increasing number 
of women who prefer to avoid menstruation.23 Careful coun-
seling about missed withdrawal bleeds prior to commencing 
this COC should reassure these women.
The convenience of a low-dose pill that can be chewed 
without the need for water will be useful in allowing women 
who have forgotten a pill to take it whenever they remember, 
provided they carry it with them.
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